Skip to content
HomeLatest newsJohnson & Johnson MedTech earns a spot on Fast Company‘s 2022 Most Innovative Companies list
johnson-johnson-medtech-earns-a-spot-on-fast-companys-2022-most-innovative-companies-list-lede-0322.jpg

Johnson & Johnson MedTech earns a spot on Fast Company‘s 2022 Most Innovative Companies list

The company is honored to be recognized for its cutting-edge approach to solving some of healthcare’s most urgent needs.

Share Article
share to

Innovation has always been at the heart of Johnson & Johnson’s mission to change the trajectory of human health around the world. Now, the company’s medtech business, which is now known as Johnson & Johnson MedTech (JJMT), is being recognized for that very attribute.

Today, the editors of Fast Company announced that JJMT has been selected as one of Fast Company’s Most Innovative Companies for 2022, recognizing it in the Health category, which singles out companies that are driving innovations in the latest devices, services and approaches to empower patients.

As part of the world’s largest and most broadly based healthcare company—and representing the world’s second largest medtech company—JJMT is pioneering the next frontier of patient care. And during a year of unparalleled healthcare challenges, Johnson & Johnson’s medtech business more than delivered.

A Year of Groundbreaking Innovation

JJMT is being honored for its success and commitment to delivering breakthrough scientific innovation and reimagining health in an increasingly digital world.

By harnessing the wealth of data generated in operating rooms around the world, JJMT’s innovations are providing greater precision and better, more accurate outcomes for patients, surgeons and the healthcare system as a whole.

By tackling the world’s most pressing healthcare challenges—across surgery, orthopedics, vision and interventional solutions—JJMT unleashes diverse healthcare expertise, purposeful technology and a passion for people to empower everyone to live their best life possible.

For example, the medtech team is bringing artificial intelligence (AI) into the operating room to provide real-time insights, more personalized interventions and improved outcomes through its AI-powered C-SATS platform. The online service allows surgeons to connect any operating room to the cloud so that they can access surgical videos, offer personalized learning and mentoring from other surgeons and connect with their peers virtually.

JJMT is also using interactive 3-D technology to arm surgeons with a clearer roadmap for surgery through the Visible Patient Planning Solution software. It’s also using a suite of tools and technologies to provide a more personalized patient care experience, greater insights for real-time decision making and technology designed to provide greater precision and consistency during orthopedic surgery through its VELYS Digital Surgery platform. And, with the Monarch® platform, JJMT is helping physicians access and visualize hard-to-reach nodules in the lungs, enabling biopsy for early diagnosis and treatment of lung disease.

By tackling the world’s most pressing healthcare challenges—across surgery, orthopedics, vision and interventional solutions—JJMT unleashes diverse healthcare expertise, purposeful technology and a passion for people to empower everyone to live their best life possible. JJMT is honored to be included on Fast Company’s list of Most Innovative Companies.

More from Johnson & Johnson

What to know about We All Belong: 2023 DEI Impact Review

The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.

Giving the gift of sight

In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.